JP2008518974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518974A5 JP2008518974A5 JP2007539372A JP2007539372A JP2008518974A5 JP 2008518974 A5 JP2008518974 A5 JP 2008518974A5 JP 2007539372 A JP2007539372 A JP 2007539372A JP 2007539372 A JP2007539372 A JP 2007539372A JP 2008518974 A5 JP2008518974 A5 JP 2008518974A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- long chain
- nkt cell
- composition according
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000581 natural killer T-cell Anatomy 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000020411 cell activation Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001414 amino alcohols Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 150000003333 secondary alcohols Chemical class 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 206010013710 Drug interaction Diseases 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical group CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62456804P | 2004-11-02 | 2004-11-02 | |
| US60/624,568 | 2004-11-02 | ||
| US70654805P | 2005-08-08 | 2005-08-08 | |
| US60/706,548 | 2005-08-08 | ||
| PCT/US2005/040182 WO2006060117A2 (en) | 2004-11-02 | 2005-11-02 | Methods for inhibition of nkt cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008518974A JP2008518974A (ja) | 2008-06-05 |
| JP2008518974A5 true JP2008518974A5 (https=) | 2008-11-27 |
| JP4948418B2 JP4948418B2 (ja) | 2012-06-06 |
Family
ID=36565493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539372A Expired - Fee Related JP4948418B2 (ja) | 2004-11-02 | 2005-11-02 | Ｎｋｔ細胞を抑制するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7682614B2 (https=) |
| EP (1) | EP1812015B1 (https=) |
| JP (1) | JP4948418B2 (https=) |
| CN (1) | CN101031307B (https=) |
| AT (1) | ATE539757T1 (https=) |
| AU (1) | AU2005310247A1 (https=) |
| CA (1) | CA2584971C (https=) |
| DK (1) | DK1812015T3 (https=) |
| ES (1) | ES2378076T3 (https=) |
| PT (1) | PT1812015E (https=) |
| WO (1) | WO2006060117A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1372668B1 (en) | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| EP2575824A4 (en) * | 2010-05-24 | 2014-02-19 | Childrens Medical Center | METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES |
| WO2012069572A1 (en) * | 2010-11-25 | 2012-05-31 | Imnate Sarl | Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells |
| EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR |
| BR112014009962A2 (pt) * | 2011-10-27 | 2019-09-24 | Nkt Therapeutics Inc | anticorpos humanizados para inkt |
| CA2925878A1 (en) | 2012-10-12 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Glycosphingolipids and methods of use thereof |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| HK1218720A1 (zh) | 2013-04-30 | 2017-03-10 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| CN107531787B (zh) | 2015-01-27 | 2022-01-18 | 拉法医疗有限公司 | 靶向cd1d的单域抗体 |
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| EP3484441A4 (en) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | GLYCOLIPID COMPOSITIONS AND METHOD FOR USE |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR102681843B1 (ko) | 2017-09-22 | 2024-07-05 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| WO2020060406A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| EP4480486A1 (en) * | 2022-02-14 | 2024-12-25 | Riken | Nkt cell ligand-containing liposome composition |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US7063844B2 (en) * | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US5679347A (en) * | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
| ES2201078T3 (es) | 1993-06-21 | 2004-03-16 | Brigham And Women's Hospital | Metodos de aislar antigenos presentados por cd1, vacunas que comprenden antigenos presentados por cd1, y lineas celulares para usar en dichos metodos. |
| US6632976B1 (en) * | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| ATE286735T1 (de) * | 1997-04-10 | 2005-01-15 | Kirin Brewery | Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten |
| JP2001515868A (ja) * | 1997-09-12 | 2001-09-25 | ブライハム アンド ウイメンズ ホスピタル | Ｃｄ１制限免疫応答のための合成抗原 |
| TW575420B (en) * | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
| US6197582B1 (en) * | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| WO2000002923A1 (en) | 1998-07-09 | 2000-01-20 | Nickoloff Brian J | Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| AU2002213588A1 (en) | 2000-06-05 | 2001-12-17 | The Brigham And Women's Hospital, Inc. | Soluble cd1 compositions and uses thereof |
| AU2001262697A1 (en) * | 2000-06-06 | 2001-12-17 | Kirin Beer Kabushiki Kaisha | Method of amplifying natural killer t cells |
| DK2336187T3 (en) * | 2000-06-19 | 2016-08-22 | Beth Israel Deaconess Medical Ct Inc | Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| WO2002016825A1 (fr) * | 2000-08-18 | 2002-02-28 | Mitsubishi Denki Kabushiki Kaisha | Douille et transformateur pour lampe et procede de fabrication d'un transformateur pour lampe |
| DE10046658A1 (de) | 2000-09-20 | 2002-04-04 | Bosch Gmbh Robert | Induktiver Übertrager und ein Verfahren zu dessen Herstellung |
| CN1487996B (zh) * | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| IL140537A0 (en) * | 2000-12-25 | 2002-02-10 | Hadasit Med Res Service | Educated nk t cells and their uses in the treatment of immune-related disorders |
| EP1372668B1 (en) * | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US6662434B2 (en) * | 2001-04-03 | 2003-12-16 | General Electric Company | Method and apparatus for magnetizing a permanent magnet |
| US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| WO2002087556A2 (en) * | 2001-04-11 | 2002-11-07 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| US20020171538A1 (en) * | 2001-05-15 | 2002-11-21 | Kuo-Hsin Su | Vehicle motion detector and control device arrangement |
| US20020171557A1 (en) * | 2001-05-18 | 2002-11-21 | Wegener William E. | Security electronic system |
| CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
| AU2003234443A1 (en) | 2002-05-01 | 2003-11-17 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
| WO2003105769A2 (en) * | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| HK1079882B (en) | 2002-06-14 | 2011-11-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing colitis involving il-13 and nk-t cells |
| US7368142B2 (en) * | 2002-08-01 | 2008-05-06 | Renew Life Formulas, Inc. | Natural sweetener |
| US20060104901A1 (en) | 2002-08-27 | 2006-05-18 | Angus Moodycliffe | Preventing or treating epithelial tissue damage or hair loss |
| WO2004028475A2 (en) | 2002-09-27 | 2004-04-08 | Biomira, Inc. | Glycosylceramide analogues |
| US20040171522A1 (en) * | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
| US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| WO2005032462A2 (en) * | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US20050032210A1 (en) * | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
| US20040235162A1 (en) * | 2003-03-18 | 2004-11-25 | Kirin Beer Kabushiki Kaisha | Method of preparing immunoregulatory dendritic cells and the use thereof |
| WO2004094444A1 (en) * | 2003-03-20 | 2004-11-04 | Brigham Young University | 6'-amino-6'-deoxygalactosylceramides |
| WO2004084874A2 (en) | 2003-03-24 | 2004-10-07 | Brigham And Women's Hospital, Inc. | Mtp inhibitors for inhibiting inflammation |
| EP1653977A2 (en) | 2003-07-17 | 2006-05-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Treatment of disorders associated with natural killer t cells |
| ES2389080T3 (es) | 2004-06-11 | 2012-10-23 | Riken | Fármaco que presenta un ligando de células reguladoras contenido en el liposoma |
-
2005
- 2005-11-02 CA CA2584971A patent/CA2584971C/en not_active Expired - Fee Related
- 2005-11-02 US US11/266,033 patent/US7682614B2/en not_active Expired - Fee Related
- 2005-11-02 CN CN2005800330994A patent/CN101031307B/zh not_active Expired - Fee Related
- 2005-11-02 ES ES05851383T patent/ES2378076T3/es not_active Expired - Lifetime
- 2005-11-02 EP EP05851383A patent/EP1812015B1/en not_active Expired - Lifetime
- 2005-11-02 AU AU2005310247A patent/AU2005310247A1/en not_active Abandoned
- 2005-11-02 WO PCT/US2005/040182 patent/WO2006060117A2/en not_active Ceased
- 2005-11-02 AT AT05851383T patent/ATE539757T1/de active
- 2005-11-02 DK DK05851383.9T patent/DK1812015T3/da active
- 2005-11-02 PT PT05851383T patent/PT1812015E/pt unknown
- 2005-11-02 JP JP2007539372A patent/JP4948418B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-01 US US12/697,882 patent/US8679499B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518974A5 (https=) | ||
| Luo et al. | Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone | |
| US10639301B2 (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | |
| Casali et al. | Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer's disease | |
| JP2016525140A5 (https=) | ||
| Tang et al. | Conjugated linoleic acid attenuates 2, 4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-κB signaling | |
| BRPI0412909A (pt) | uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer | |
| EP2687220A3 (en) | Treatment of inflammatory diseases using placental stem cells | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| JP2010518029A5 (https=) | ||
| JP2022101529A (ja) | アレルギー疾患の治療方法 | |
| JP6609320B2 (ja) | ノカルダミンの新規金属錯体および医薬組成物におけるそれらの使用 | |
| Kyung et al. | Synergistic anti-inflammatory effects of Laminaria japonica fucoidan and Cistanche tubulosa extract | |
| BR0014946A (pt) | Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina | |
| Padmanaban et al. | Curcumin may defy medicinal chemists | |
| Tollesson et al. | Malassezia furfur in infantile seborrheic dermatitis | |
| WO2022256291A1 (en) | Hydrogel devices for drug delivery to the ear | |
| Eberting | Irritant contact dermatitis: mechanisms to repair | |
| Beray-Berthat et al. | Long-term histological and behavioural characterisation of a collagenase-induced model of intracerebral haemorrhage in rats | |
| Nowak-Machen et al. | Lysophosphatidic acid generation by pulmonary NKT cell ENPP-2/autotaxin exacerbates hyperoxic lung injury | |
| Yanık et al. | Current neuroprotective agents in stroke | |
| FR3130140B1 (fr) | Agent de traitement capillaire avec effet de soin amélioré | |
| Strosznajder et al. | Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress | |
| BRPI0409456A (pt) | métodos para o tratamento e/ou prevenção de doenças ligadas ao acúmulo de triglicerìdeos em tecidos e sangue, de doenças ligadas a uma falta de equilìbrio de colesterol em prejuìzo de colesterol hdl em tecidos e sangue, métodos de tratamento para diminuir os nìveis no sangue de triglicerìdeos, para equilibrar o nìvel no sangue e/ou tecidos de colesterol total em favor de colesterol hdl, para abaixar os nìveis de triglicerìdeo no fìgado, método para o tratamento ou prevenção de uma condição obesa, método de tratamento para a redução ou inibição do ganho de gordura corporal, método para aliviar a resistência ou restaurar a sensibilidade a insulina, uso de ácido beta-aminoisobutìrico, derivado, prodroga, metabólito ou complexo do mesmo, composição farmacêutica, composição nutricional, e, método para produzir redução de massa de gordura |